|
WO2020068510A1
|
|
Abuse deterrent immediate release capsule dosage forms
|
|
BR112020011614A2
|
|
ONE STEP MILLING PROCESS TO PREPARE MICRONIZED PALIPERIDONE ESTERS
|
|
CA3081841A1
|
|
Process for preparing acylated amphetamine derivatives
|
|
MX2019013970A
|
|
Delayed sustained release pharmaceutical compositions.
|
|
AU2017241266A1
|
|
Extended release, abuse deterrent dosage forms
|
|
BR112018014839A2
|
|
glucomannan containing prolonged release pharmaceutical compositions and properties to prevent misuse
|
|
AU2016292797A1
|
|
A two-step process for preparing 3-substituted phenylalkylamines
|
|
AU2015275098A1
|
|
Spray dried compositions having different dissolution profiles and processes for their preparation
|
|
MX2016005624A
|
|
Preparation of normorphinans.
|
|
AU2014346883A1
|
|
Production of 6-hydroxy morphinans without the isolation of intermediates
|
|
AU2014342096A1
|
|
Convenient preparation of N-substituted morphinan-6-ols from morphinan-6-ones
|
|
AU2014200890A1
|
|
Processes and compounds for the preparation of normorphinans
|
|
AU2013205836A1
|
|
Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
|
|
AU2011245437B2
|
|
Preparation of saturated ketone morphinan compounds having low metal content
|
|
AU2009300386A1
|
|
Processes for the alkylation of norbuprenorphine with reduced impurity formation
|
|
AU2009300390A1
|
|
Processes for the production of buprenorphine with reduced impurity formation
|
|
AU2009251427A1
|
|
Processes and compounds for the preparation of normorphinans
|
|
AU2008338906A1
|
|
Processes for the production of (+)-'nal' morphinan compounds
|
|
AU2008321205A1
|
|
Indole grafted solid support for Fmoc-solid phase peptide synthesis
|
|
MX350380B
|
|
Zero-order modified release solid dosage forms.
|
